2022-09-06 | NDAQ: SPNE | Press release
CARLSBAD, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company specializing in surgical solutions for the treatment of spinal disorders, today announced the Full commercial launch of the WaveForm TA Interbody System (TLIF Articulating).
The WaveForm TA Interbody System is designed to provide an interbody to the anterior portion of the disc space to optimize sagittal alignment and endplate support. With an array of impression and lordosis options to choose from, surgeons have the ability to address specific anatomical needs intraoperatively and without impeding surgical workflow.
“WaveForm TA is an exciting addition to our interbody portfolio and provides a premier offering in what we estimate to be the $175 million TLIF US market for solid and 3D printed titanium products,” said Dennis Cirino , Senior Vice President, Global Spinal Systems. “This system provides a versatile and reproducible lumbar interbody solution, while delivering efficiency through cross-compatible instrumentation. This allows surgeons to choose from multiple SeaSpine implant families with one familiar instrument set.”
WaveForm interbody devices offer the next level of 3D printed architectural innovation, balancing major geometric and manufacturing advancements without compromising clinical requirements. The WaveForm TA interbody system utilizes innovative WaveForm technology to provide a highly porous, yet robust architecture intended to optimize collapse resistance, implant stiffness, and orthobiologic compressive capability, while maintaining radiographic visualization during intraoperative and postoperative imaging.
“The WaveForm TA implant has a very thoughtful design. Porosity allows for bone growth while balancing ideal roughness,” said Dr. Alex Mohit of NeoSpine and Tacoma General Hospital. “The simple and effective instrumentation has been refined to insert the implant safely and precisely. I was extremely impressed with the results.”
About Sea Spine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients with spinal disorders. SeaSpine’s comprehensive procedural solutions include its market-leading FLASH™ navigation, a system designed to improve screw placement accuracy and provide a cost-effective, time-saving and radiation-free solution for surgical navigation, as well as a comprehensive portfolio of spinal and orthobiologic implants to meet the diverse product combinations neurosurgeons and orthopedic spine surgeons need to facilitate spinal fusion in minimally invasive degenerative surgery (MIS) and complex spinal deformity procedures on the lumbar spine , thoracic and cervical. With product development expertise in the areas of advanced optics, software, orthobiologic sciences and spinal implants, SeaSpine can offer its surgeon customers a complete solution to meet their patients’ evolving clinical needs. SeaSpine currently markets its products in the United States and in approximately 30 countries around the world.
Forward-looking statements
SeaSpine cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements based on the company’s current expectations and assumptions. These forward-looking statements include, but are not limited to, statements relating to: the design of WaveForm TA and its ability to provide a versatile lumbar interbody solution for surgeons; the ability of WaveForm TA to balance major geometric and manufacturing advancements without compromising clinical utility; the ability of WaveForm technology to provide a highly porous and robust interbody solution and to appropriately balance resistance to collapse, implant stiffness and orthobiologic compression capability, while maintaining radiographic visualization during intraoperative and postoperative imaging. Among the factors that could cause or contribute to material differences between the company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties, which include, but are not limited to: unexpected expenses and delays, including as a result of developing and supporting the launch of new products, such as WaveForm TA, the fact that newly launched products may require substantial additional development activities, which could result in additional expense and delays, or due a delay in obtaining regulatory approvals in a timely manner; the ability of newly launched products, such as WaveForm TA, to perform as intended and meet the needs of surgeons and patients, particularly due to the lack of substantial clinical validation of the products after limited commercialization (or “alpha”) launch; and other risks and uncertainties more fully described in press releases and the Company’s periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they were made. SeaSpine does not intend to revise or update forward-looking statements set forth in this press release to reflect events or circumstances occurring after the date hereof, except as required by law.
Investor Relations
Leigh Salve
(415) 937-5402
ir@seaspine.com
A photo accompanying this ad is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9f8115f4-dc75-4446-9d4f-83adcc7669ae
